Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TYR | P14679 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | RARG | P13631 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216935 | 0.90 | L3MBTL1 (0.53) | LMNATYRHDAC1SRD5A2TSHR | |
| SCHEMBL1176728 | 0.81 | HDAC1 (0.61) | LMNATYRHDAC1SRD5A2ALDH1A1 | |
| SCHEMBL424728 | 0.80 | TSHR (0.73) | LMNATYRHDAC1SRD5A2TSHR | |
| SCHEMBL14471516 | 0.80 | SRD5A2 (0.58) | LMNATYRHDAC1SRD5A2TSHR | |
| SCHEMBL7965283 | 0.80 | LMNA (0.55) | LMNATYRHDAC1SRD5A2TSHR | |
| SCHEMBL23709159 | 0.78 | LMNA (0.52) | LMNATYRHDAC1SRD5A2TSHR | |
| SCHEMBL1148445 | 0.78 | SRD5A2 (0.83) | LMNATYRHDAC1SRD5A2ALDH1A1 | |
| SCHEMBL14062460 | 0.78 | LMNA (0.52) | LMNATYRHDAC1SRD5A2TSHR | |
| SCHEMBL2853873 | 0.78 | HDAC1 (0.64) | LMNATYRHDAC1SRD5A2ALDH1A1 | |
| SCHEMBL10946728 | 0.78 | SRD5A2 (0.83) | LMNATYRHDAC1SRD5A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| US-20050159374-A1 | 2'-Substituted nucleosides and oligonucleotide derivatives | NOVARTIS AG (CH) | 2005-07-21 | — | — | US | claimed |
| EP-0906329-B1 | 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES | NOVARTIS AG (CH) | 2003-10-08 | — | — | EP | claimed |
| EP-0885237-B1 | OLIGONUCLEOTIDE ANALOGUES | ISIS PHARMACEUTICALS INC (US) | 2003-09-10 | — | — | EP | claimed |
| US-6562960-B1 | Oligonucleotide analogues | ISIS PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | claimed |
| EP-0906329-A2 | 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES | Novartis AG (CH) | 1999-04-07 | — | — | EP | claimed |
| EP-0885237-A1 | OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1998-12-23 | — | — | EP | claimed |
| WO-1997046569-A2 | 2'-SUBSTITUTED NUCLEOSIDES AND OLIGONUCLEOTIDE DERIVATIVES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | claimed |
| WO-1997032887-A1 | OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | claimed |
| CN-118139851-A | Antitumor compounds | 法马马有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| WO-2024074604-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | INSTITUTO BIOMAR, S.A (ES) | 2024-04-11 | — | — | WO | disclosed |
| EP-4349409-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | Instituto Biomar S.A. (ES) | 2024-04-10 | — | — | EP | disclosed |
| EP-0741741-A1 | MODIFIED OLIGONUCLEOTIDES | Novartis AG (CH) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020597-A1 | MODIFIED OLIGONUCLEOTIDES | CIBA-GEIGY AG (CH) | 1995-08-03 | — | — | WO | disclosed |
| EP-0644196-A1 | TTTr as a protecting group in nucleotide synthesis | CIBA-GEIGY AG (CH) | 1995-03-22 | — | — | EP | disclosed |
| US-5268464-A | Process for the preparation of nucleosides | CIBA-GEIGY CORPORATION (US) | 1993-12-07 | — | — | US | disclosed |
| EP-0563010-A2 | Method of preparation of nucleosides | CIBA-GEIGY AG (CH) | 1993-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | LMNA 1254/4885TYR 428/4885HDAC1 1513/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | LMNA 1898/4885TYR 808/4885HDAC1 676/4885 |
| US-20050159374-A1 | 2'-Substituted nucleosides and oligonucleotide derivatives | TYMP, NUDT1, POLB | LMNA 1403/4885TYR 4341/4885HDAC1 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.